Clinical Trial Update: A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards. [Phase 4]

View source ↗

Summary

Phase 4 trial assessing safety and reactogenicity of Cervarix HPV vaccine in healthy Filipino girls aged 10+; study terminated with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection Leading to Cervical Cancer

Drugs mentioned

• Cervarix (human papillomavirus vaccine, bivalent)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Human Papillomavirus Infection Leading to Cervical Cancer | Phase 4 | Status: TERMINATED | Results posted: 2012-12-21